Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer

Yoshinao Abe, Taiju Matsuzawa, Takehiko Fujiwara, Masatoshi Itoh, Hiroshi Fukuda, Keiichirou Yamaguchi, Kazuo Kubota, Jun Hatazawa, Masao Tada, Tatsuo Ido, Shouichi Watanuki

Research output: Contribution to journalArticlepeer-review

56 Citations (Scopus)

Abstract

Using positron emission tomography, we studied the tumor uptake of 18F-2-fluoro-2-deoxy-D-glucose (18FDG) in five lung cancer patients before and after anti-cancer therapy (radiotherapy and/or chemotherapy). The tumor uptake of 18FDG was classified as positive and negative; the former, by increasing the uptake of 18FDG with time, and the latter, by decreasing or the constant uptake of 18FDG. Before therapy, all cases tested positive. After therapy, three cases were negative and two cases remained positive. All negative cases corresponded to complete responses, and positive cases showed partial responses accompanying tumor regrowth 2 or 3 months after the second 18FDG study. Our findings in the 18FDG study correlate with the clinical results. 18FDG is a promising method for assessing therapeutic effects on cancer clinically.

Original languageEnglish
Pages (from-to)1005-1010
Number of pages6
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume19
Issue number4
DOIs
Publication statusPublished - 1990 Oct

Keywords

  • F-2-fluoro-2-deoxy-D-glucose
  • Lung cancer
  • Positron emission tomography
  • Therapeutic effects of cancer

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical assessment of therapeutic effects on cancer using <sup>18</sup>F-2-fluoro-2-deoxy-d-glucose and positron emission tomography: Preliminary study of lung cancer'. Together they form a unique fingerprint.

Cite this